SENORESBSESenores Pharmaceuticals Ltd· Pharmaceuticals & BiotechnologyHighPositive
Announced Tue, 17 Feb, 2026 · 10:29 IST

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 16, 2026 for Renosen Pharmaceuticals Pvt Ltd

Pledge ReleasedOwnership Changes View source PDFExplain this filing

SENORES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+0.1%Reaction day
₹791.15
prior close
₹795.70
announcement price
In-mkt
timing
Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.0%-0.9% vs market
Pharmaceuticals peers, median of 157sector+0.2%-0.2% vs sector

On the reaction day the stock moved 0.9 pts less than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.4
10m
+0.5
15m
+0.0
30m
-0.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+0.1+1.0-0.9+0.2-0.2
Next day
+3.9+1.3+2.6+0.6+3.2
2d
+2.5-0.2+2.7-0.4+2.9
3d
+2.5-0.3+2.8-0.6+3.1
4d
+0.3-0.2+0.5-0.3+0.6
5d
-1.0-1.4+0.4-1.6+0.6
1w
-1.3-1.0-0.3-0.6-0.7
15d
-6.5-6.3-0.2-4.2-2.3
1m
-5.4-9.0+3.6-5.8+0.4
2m
+12.9+3.5+9.4+1.4+11.4
3m
+43.2+4.6+38.6+4.1+39.1
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Senores Pharmaceuticals informed the exchanges about a pledge release by Renosen Pharmaceuticals Private Limited, a Promoter Group entity. The pledge on 4,00,000 equity shares (about 0.87% of total share capital) was released on February 13, 2026, with the disclosure filed on February 16, 2026. After this release, Renosen Pharmaceuticals holds 27,08,719 shares (5.88% of total capital) with zero encumbered shares remaining. The disclosure was made under SEBI's SAST Regulations, 2011. Other promoter and promoter group entities listed in the table show no changes to their pledged holdings in this filing.

Likely market impact

This is a positive signal for shareholders — the promoter group has reduced its pledged holdings to zero, lowering the risk of any forced selling or margin-call driven share dump. It also suggests improved liquidity or loan repayment by the promoter group entity.